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Abstract Activated p38Q MAP kinase exhibited significant
basal ATPase activity in the absence of a kinase substrate, and
addition of a phosphoacceptor substrate increased kcat/Kms 20-
fold. AMP-PCP was competitive with ATP binding and non-
competitive with phosphoacceptor substrate binding. The nucleo-
tide binding site affinity label 5P-(p-fluorosulfonylbenzoyl)ade-
nosine (FSBA) bound stoichiometrically at Lys-56 in the ATP
site of both unphosphorylated and activated p38Q. AMP-PCP
only protected the activated enzyme from FSBA inactivation,
implying that AMP-PCP does not bind unphosphorylated p38Q.
Basal ATPase activities were also observed for activated p38K,
ERK2 and JNK3 suggesting that the enzymatic mechanism may
be similar for all classes of MAP kinases.
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1. Introduction
The mitogen-activated protein (MAP) kinase family are
serine/threonine kinases that mediate intracellular signal
transduction pathways [1,2]. This family contains three se-
quence and structurally similar classes of enzymes: the extra-
cellular signal regulated kinases (ERKs), Jun N-terminal ki-
nases (JNKs) and p38 kinases. These kinases are activated by
phosphorylation of both threonyl and tyrosyl sidechains ar-
ranged in a Thr-X-Tyr motif, where X represents a Glu, Pro
and Gly in ERK, JNK and p38 kinases, respectively [1,3].
ERKs are activated by mitogens and growth factors [4],
whereas the JNK and p38 kinases are activated in response
to pro-in£ammatory cytokines and by cellular stress [5^7].
MAP kinases use ATP to phosphorylate various regulatory
proteins including 90 kDa ribosomal s6 kinase (Rsk90) and
MAPK-activated protein kinase-2 (MAPKAP2) [8], as well as
transcription factors such as activating transcription factor 2
(ATF2) [9,10], Elk1 [9,11], c-Fos [12], c-Myc [13], c-Jun [14],
NFAT [15] and DENN [16].
p38Q MAP kinase shows 61% amino acid sequence identity
with p38K, but is expressed predominantly in skeletal muscle
tissue [17,18]. In contrast, p38K is found in a variety of tissues.
The di¡erent tissue distribution suggests p38Q may have a
di¡erent function than p38K MAP kinase, although this is
not currently known.
This study was designed to analyze the kinetic mechanism
and ATP-binding site reactivity of p38Q MAP kinase using
ATP analogs. We present data indicative of a mechanism in
which substrates bind to p38Q either in a random manner, or
possibly in an ordered manner, with ATP binding ¢rst. ATP
and phosphoacceptor substrates have no observable e¡ect on
the binding of one another and the kinetic mechanism is
independent of the phosphoacceptor size (i.e. peptide or pro-
tein). The non-hydrolyzable ATP analog, L,Q-methylene-
adenosine 5P-triphosphate (AMP-PCP), is a competitive inhib-
itor of ATP binding and a non-competitive inhibitor of
epidermal growth factor receptor (EGFR) peptide and GST-
ATF2 binding to p38Q. We observe signi¢cant basal ATPase
activity for all activated p38, ERK and JNK members
studied, which eliminates a mechanism requiring that kinase
substrate binding precedes ATP binding for any of the MAP
kinases in this study.
2. Materials and methods
2.1. Materials
14C-5P-(p-£uorosulfonylbenzoyl)adenosine (FSBA) was purchased
from NEN Life Science Products (Boston, MA, USA), horse heart
myoglobin, AMP-PCP, ATP and FSBA were obtained from Sigma
(Saint Louis, MO, USA). SB202190 and SB203580 were purchased
from Upstate Biotechnology, Lake Placid, NY, USA.
2.2. Expression of kinases
We obtained an EST clone (#163561) containing the human cDNA
encoding p38Q kinase from Research Genetics (Huntsville, AL, USA).
A cDNA fragment encoding an N-terminal (His)6 tagged p38Q kinase
was ampli¢ed by PCR using a pair of forward and reverse primers:
5P-GGATCCATGGGCCATCACCATCACCATCACGCCAGCTC-
TCCGCCGCCCGG-3P and 5P-GGATTCGAATTCCTATCACAGA-
AGGGCGTCTCCTTG-3P. The ampli¢ed cDNA fragment was di-
gested with NcoI and EcoRI and cloned into the expression vector
pET-BS(+). Escherichia coli BL21(DE3) was transformed with the
plasmid pET-BS(+)/(His)6-p38Q and grown at 30‡C to an OD550 of
0.8^1.0 and protein expression induced with 1 mM IPTG for 3 h.
Bacteria were harvested and stored at 370‡C prior to use.
2.3. Protein puri¢cation
E. coli cell paste expressing (His)6-p38Q was resuspended in 10 vol-
umes/g of Bu¡er A (50 mM HEPES pH 8.0, 200 mM NaCl, 2 mM
L-mercaptoethanol (L-ME), 10% glycerol and 0.2 mM phenylmethyl-
sulfonyl £uoride (PMSF)). Following mechanical disruption of the
cells in a Micro£uidizer (Micro£uidics, Newton, MA, USA), the ly-
sate was centrifuged at 30 000Ug for 30 min at 4‡C. The supernatant
was incubated batch-wise overnight at 4‡C with 1 ml of Talon metal
a⁄nity resin (Clontech, Palo Alto, CA, USA) per 5 mg of expected
p38Q. The resin was settled by centrifugation at 500Ug and washed
batch-wise with Bu¡er A at 4‡C. The resin was washed with 10 col-
umn volumes of bu¡er A +7.5 mM imidazole. The p38Q was eluted
with Bu¡er A +100 mM imidazole and dialyzed overnight at 4‡C vs.
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50 mM HEPES, pH 7.5, 50 mM NaCl, 5% glycerol, 2 mM dithio-
threitol (DTT). The protein was further puri¢ed on a MonoQ (HR 10/
10) column (Pharmacia, Uppsala, Sweden), as described below, for
either unphosphorylated enzyme or following activation. E. coli cell
paste expressing GST-ATF2 was lysed and centrifuged as described
for p38Q (no L-ME in the bu¡er) and incubated batch-wise with 1 ml
glutathione agarose (Sigma, St Louis, MO, USA)/ 5 mg of expected
protein for 3 h at 4‡C. The resin was washed with 20 column volumes
of bu¡er A and eluted with the same bu¡er containing 10 mM re-
duced glutathione at 4‡C. GST-ATF2 was further puri¢ed by size-
exclusion chromatography using a Sephacryl S100 (Pharmacia, Upp-
sala, Sweden) column equilibrated in bu¡er A at 4‡C using a £ow rate
of 0.4 ml/min. GST-ATF2 was concentrated in a Centriprep-50 (Ami-
con, Beverly, MA, USA) to 10^20 mg/ml and stored at 370‡C.
2.4. Activation of p38Q
A constitutively active mutant of MAP kinase kinase (MKK)6 was
expressed and puri¢ed as described [19]. Typically, 10^15 mg of p38Q
was diluted to 0.5 mg/ml in bu¡er B. MKK6(DD) was added at 20 Wg/
ml and the activation initiated by addition of ATP in six separate
0.5 mM (¢nal concentration) increments at 5 min intervals. After
30 min the activation mixture was ¢ltered through a 0.2 Wm ¢lter
and applied to a MonoQ (HR 10/10) column (Pharmacia, Uppsala,
Sweden) equilibrated in bu¡er B. The column was washed to baseline
with bu¡er B and eluted with a 20 column volume gradient to bu¡er
B containing 0.4 M NaCl. The activated p38Q peak was pooled, dia-
lyzed at 4‡C versus bu¡er B, and stored at 370‡C.
2.5. Kinase assays
A previously described coupled spectrophotometric assay was used
to follow ATPase and kinase activities [20]. Reactions were performed
in 50 mM HEPES, pH 7.6, 10 mM MgCl2, and started by addition of
15^1000 WM ATP as described. Addition of 0^2 mM of the peptide
KRELVEPLTPSGEAPNQALLR, corresponding to an EGF receptor
substrate peptide [21], allowed measurement of kinase activity. Alter-
natively, 0^400 WM GST-ATF2 was added to measure kinase activity.
In Ki determinations, enzyme and inhibitor were pre-incubated for
15 min at 30‡C prior to assay by ATP addition. Enzyme kinetics
analyses were performed by non-linear regression in the program
EZ-Fit (Perrella Scienti¢c, Amherst, NH, USA).
2.6. FSBA labeling of MAP Kinases
Two molar equivalents of 14C-FSBA were added to 2.5 WM un-
phosphorylated or activated MAP kinase at 25‡C in 50 mM HEPES,
pH 7.6, 10 mM MgCl2 and 2 mM DTT, in the presence or absence of
protein or peptide kinase substrate. ATP-binding site competition ex-
periments were performed as above in the presence of 1.2 mM AMP-
PCP. Reactions were quenched at various time points by addition of
SDS-PAGE sample bu¡er, and the modi¢ed MAP kinases separated
by SDS-PAGE, ¢xed and visualized by phosphorimaging and auto-
radiography.
2.7. Protein sequencing
Two molar equivalents of FSBA in DMSO were added to 250 Wg of
unphosphorylated or activated p38Q. Control samples of p38Q were
treated with DMSO. Samples were incubated at 25‡C for 2 h. Fifty
microgram samples were then loaded on a HP1100 HPLC system
utilizing a 2U150 mm C18 reversed phase column (Phenomenex, Tor-
rance, CA, USA) and a TFA/acetonitrile gradient system. Intact pro-
teins were eluted from the column with a linear gradient, collected and
lyophilized for mass spectral analysis. The remaining 200 Wg of each
sample was exchanged into 50 mM HEPES, pH 7.5, for in vitro
proteolysis. Lys-C protease (8 Wg) was added to each sample and
incubated at 37‡C for 16 h. Peptides were separated as above and
the FSBA-modi¢ed peptide identi¢ed by LC-MS di¡erence maps.
The peptide identity was con¢rmed by traditional N-terminal protein
sequencing.
2.8. Mass spectral analysis of puri¢ed proteins
Electrospray mass spectra of protein samples were collected using a
Micromass Quattro II triple quadrupole mass spectrometer. Lyophi-
lized protein samples were dissolved in a 50:50 (acetonitrile :water)
solution with 0.2% formic acid and introduced at a £ow rate of
20 Wl/min. Data were collected by scanning the ¢rst quadrupole
with a step size of 8 points per Da and the resolution was adjusted
to 0.65 m/z over the scanned mass to charge range of 500^2000 m/z.
The quadrupole was calibrated using horse heart myoglobin before
and after p38Q data collection. Data deconvolution was performed
using the MassLynx software BioTools (Micromass, Bedford, MA,
USA).
3. Results
3.1. Activation of p38Q
p38Q was activated using a constitutively active mutant of
MKK6, the immediate upstream MAPK kinase responsible
for activating p38. In this mutant, the phosphorylation sites,
Ser-207 and Thr-211, are substituted with Asp residues [9,22].
A comparison of the molecular weights of unphosphorylated
and activated p38Q by mass spectrometry showed an increase
of 239 Da, due to phosphorylation at three sites. Digestion of
activated p38Q with Lys-C protease, followed by protein se-
quencing, identi¢ed the sites as Tyr-183 and Thr-185, in the
activation lip, and Ser-3 near the N-terminal portion of the
enzyme. Control experiments demonstrated that activated
Fig. 1. Eadie-Hofstee plots of v (WM/min) versus v/[S] for AMP-
PCP inhibition of activated p38Q MAP kinase. A: ATPase activity
at 15^500 WM ATP in the presence of 0 (a), 300 (b), 600 (E) and
1200 (F) WM AMP-PCP. B: Kinase activity versus [ATP] at 200 WM
GST-ATF2 in the presence of 0 (a), 300 (b), 600 (E) and 1200 (F)
WM AMP-PCP. C: Kinase activity versus GST-ATF2 at 120 WM
ATP in the presence of 0 (a), 300 (b), 600 (E) and 1200 (F) WM
AMP-PCP. See Section 2 for more details.
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p38Q was responsible for phosphorylation at Ser-3 and that
this phosphorylation has no e¡ect on the enzymatic activity of
p38Q.
3.2. ATPase activity of activated p38Q
ATP was hydrolyzed by activated p38Q in the absence of a
phosphoacceptor with a Km of 37 WM and a kcat of 0.33 s31
for ATP, which yielded a kcat/Km of 8900 M31s31 (Table 1).
AMP-PCP, a hydrolysis-resistant ATP analog, was a compet-
itive inhibitor of ATP (Kis = 125 WM) as shown by an Eadie-
Hofstee plot for AMP-PCP inhibition (Fig. 1A). These ¢nd-
ings demonstrate that a phosphoacceptor substrate was not
required for ATP or AMP-PCP binding to activated p38Q.
3.3. Kinase activity of activated p38Q
Addition of an EGFR peptide substrate during ATP turn-
over by p38Q yielded a 26-fold increase in kcat/Km compared to
the basal ATPase activity (Table 1). The Km’s for ATP bind-
ing in the kinase and ATPase reactions were similar, indicat-
ing that the enhanced kinase speci¢city constant was primarily
due to a 38-fold increase in kcat. Similarly, GST-ATF2 stimu-
lated the activity of p38Q (22-fold) due mainly to an increase
in kcat (Table 1). The binding synergy between the two sub-
strates was determined from the ratio of Km MgATP(ATPase)/
Km MgATP(kinase), and was 0.7 for the EGFR peptide, and 1.4
when GST-ATF2 is the phosphoacceptor. These ¢ndings
demonstrate a lack of binding synergy between ATP and
the phosphoacceptor substrates for p38Q MAP kinase.
The Km values for EGFR peptide and GST-ATF2 binding
to activated p38Q at saturating ATP were similar, 313 and 254
WM, respectively (Table 1). Non-linear regression analyses of
AMP-PCP inhibition, as the phosphoacceptor substrate con-
centration was varied, yielded poor ¢ts for both competitive
and uncompetitive inhibition models. Linearizing the ¢tted
data in the form of Eadie-Hofstee plots for varied EGFR
peptide or GST-ATF2, at saturating ATP, produced parallel
lines for di¡erent AMP-PCP concentrations (Fig. 1C). This
suggests AMP-PCP acts as a non-competitive inhibitor versus
the EGFR peptide and GST-ATF2. A non-competitive mech-
anism implies that AMP-PCP binds independently of the
phosphoacceptor substrate (EGFR peptide or GST-ATF2)
and that MgATP is not required to bind ¢rst.
3.4. ATPase activity of other activated MAP kinases
The observation of basal ATPase activity for activated p38Q
rules out a mechanism requiring phosphoacceptor to bind
prior to ATP. This ¢nding is inconsistent with a previously
published mechanism for p38K, which suggested that the
phosphoacceptor substrate binding had to precede that of
ATP [23]. To address whether there are mechanistic di¡eren-
ces within the same enzyme family we tested MAP kinases
from the p38, ERK and JNK classes for basal ATPase activ-
ity. The activated form of every MAP kinase tested exhibited
signi¢cant basal ATPase activity (Table 2), suggesting that
none of these enzymes, at least in vitro, have a kinetic mech-
anism requiring the phosphoacceptor substrate to bind ¢rst.
ERK2 and p38K showed the weakest basal ATPase activity,
6and 4-fold lower than p38Q, respectively. Interestingly, JNK3
showed a signi¢cantly higher level of basal ATPase activity,
9-fold higher than p38Q and up to 55-fold higher than ERK2
(Table 2).
Mass spectrometry was used to show that the unphosphory-
lated MAP kinases in this study contain no detectable acti-
vated enzyme prior to in vitro activation. Upon in vitro acti-
vation and repuri¢cation, s 95% of the enzyme was activated.
These observations are consistent with Western blot analyses
(anti-phospho antibodies) and the di¡erent chromatographic
behavior of the unphosphorylated and activated MAP ki-
nases.
3.5. A⁄nity labeling by FSBA
p38Q is insensitive to pyridinyl imidazole compounds includ-
ing SB202190 and SB203580 so we sought other inhibitors to
further probe the ATP-binding site.
FSBA is an a⁄nity label for nucleotide binding sites that,
unlike the non-hydrolyzable AMP-PCP, binds irreversibly to
the sidechain of a critical, conserved Lys residue found in the
ATP-binding site of most kinases [24]. FSBA is similar in
structure to ATP (Fig. 3). Substrate binding to p38Q MAP
kinase was characterized using FSBA. The irreversible mod-
i¢cation of the ATP-binding site of p38Q MAP kinase was
monitored by 14C-FSBA incorporation into unphosphorylated
or activated enzyme, in the presence and absence of AMP-
PCP. The FSBA a⁄nity label irreversibly bound to both un-
phosphorylated and activated p38Q, but reacted more rapidly
with unphosphorylated p38Q (compare Fig. 2A and B). The
presence of AMP-PCP had no e¡ect on 14C-FSBA incorpo-
Table 1
Kinetic constants and mode of inhibition for activated p38Q-catalyzed basal ATPase and kinase reactions
Activity Substrate kcat (s31) KM (WM) kcat/KM (M31 s31) Inhibition constants (WM) Inhibition
patterna
Fixed Varied Kis Kii
ATPase ^ ATP 0.33 þ 0.04 37 þ 3.6 8 900 125 þ 15 ^ C
Kinase EGFR ATP 12.4 þ 0.75 54 þ 9.0 230 000 121 þ 20 ^ C
Kinase ATP EGFR 14.4 þ 0.63 313 þ 30 46 000 ^ 372 þ 28 NC
Kinase GST-ATF2 ATP 5.4 þ 0.14 27 þ 1.0 200 000b 177 þ 13 ^ C
Kinase ATP GST-ATF2 5.5 þ 0.21 254 þ 24 21,650 ^ 590 þ 20 NC
aC = competitive inhibition and NC = non-competitive inhibition
bDoes not represent a true kcat/KM because GST-ATF2 is not present at saturating concentrations
Table 2
Kinetic parameters for basal ATPase activities exhibited by acti-
vated p38K, p38Q, ERK2 and JNK3
MAP Kinase kcat (s31) KM (WM) kcat/KM (M31 s31)
p38Ka 0.40 170 2 350
p38Q 0.33 37 8 900
ERK2 0.17 118 1 440
JNK3 1.04 13 80 000
ap38K data kindly provided by Sam Pazhanisamy (personal commu-
nication).
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ration for the unphosphorylated enzyme. In contrast, the rate
and extent of 14C-FSBA incorporation into activated p38Q
was signi¢cantly lower with added AMP-PCP (Fig. 2B). The
inability of the unphosphorylated p38Q to bind ATP could
explain why this enzyme exhibits no basal ATPase or kinase
activities. Incubating either form of p38Q with EGFR peptide
prior to addition of 14C-FSBA had no e¡ect on the incorpo-
ration of the a⁄nity label and did not alter the protective
e¡ect of AMP-PCP (not shown). The data in Fig. 2 show
that the incorporation of 14C-FSBA was up to 0.6 mol per
mol of protein, i.e. sub-stoichiometric, yet the reaction ap-
peared to be leveling o¡. We suspected this was due to signal
quenching in the 14C-FSBA labeling experiments, rather than
having a population of protein unable to bind FSBA. We
addressed this question by protein sequencing and mass spec-
tral analysis as shown in the next section.
3.6. Protein sequencing and mass spectral analyses of FSBA
modi¢ed p38Q
The site of FSBA modi¢cation on p38Q, as well as the re-
action stoichiometry, were identi¢ed by incubating either un-
phosphorylated or activated p38Q with FSBA. The unphos-
phorylated protein was found to have a molecular weight of
41 573 which is 432 Da higher than unmodi¢ed p38Q, indicat-
ing the presence of a single FSBA per enzyme (the expected
increase is 433 Da). Similarly, for activated p38Q, the molec-
ular weight increased from 41 380 to 41 815 Da upon FSBA
modi¢cation (i.e. a 435 Da di¡erence). FSBA-modi¢ed pro-
tein was digested with Lys-C protease and the reversed phase
HPLC peptide map compared with that of unmodi¢ed p38Q.
The overlaid digest maps for p38Q and FSBA-modi¢ed p38Q
appeared identical except for the shifted retention time of one
peptide that exhibited an absorbance peak centered at 245
nm, characteristic of FSBA derivatives [24]. No other peptide
peaks showed this absorbance pro¢le. Protein sequencing
identi¢ed the peptide as VAIKK, although sequence data
were not obtained for the fourth cycle in the treated peptide
analysis, due to modi¢cation of this Lys residue with FSBA.
Mass spectrometry con¢rmed the identity of this modi¢ed
peptide giving a molecular weight of 990.5 Da, corresponding
to the expected mass of covalently bound FSBA (i.e. VAIKK
+433 Da). There was no evidence for the presence of unmodi-
¢ed protein in any FSBA-treated samples, which together with
the whole protein mass spectral data, strongly suggest that all
the p38Q is competent to bind the a⁄nity label and that the
reduced signal was due to quenching in the 14C-FSBA labeling
experiments.
4. Discussion
Structural information for p38K, ERK2, JNK3, and most
recently p38Q [25], MAP kinases has provided an excellent
understanding of MAP kinase activation and inhibition. In
contrast, details of the catalytic mechanism has been lacking,
with only one report directly addressing the kinetic mecha-
nism for a MAP kinase [23]. We have investigated the kinetic
mechanism and ATP-binding site reactivity of p38Q, a closely
related homolog of p38K. There is considerable con£icting
data in the literature concerning the substrate speci¢city of
p38Q and the e¡ect of pyridinyl imidazole inhibitors on this
enzyme [17,18,26]. Our observations that ATF2 was an e¡ec-
tive substrate for p38_(Fig. 1C and Table 1) and that neither
SB202190 or SB203580 exhibit any inhibition of p38Q, at con-
centrations up to 20 WM, clari¢es some of the confusion. In
addition, we identi¢ed three phosphorylation sites, Tyr-183
and Thr-185 in the activation lip, and Ser-3 near the N-ter-
minal portion of the enzyme. Cuenda et al. [27] ¢rst reported
that p38Q was phosphorylated at a third site, which they
speculated could be Ser-3 and/or Ser-281, which both precede
Fig. 3. Structures of ATP and FSBA.
Fig. 2. 14C-FSBA Incorporation into p38Q MAP kinase. A: Un-
phosphorylated enzyme in the absence (a) and presence (b) of
1.2 mM AMP-PCP. B: Activated enzyme in the absence (a) and
presence (b) of 1.2 mM AMP-PCP
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a Pro residue. Our data demonstrate that Ser-3, but not Ser-
281, is phosphorylated and that this is an autophosphoryla-
tion event catalyzed by activated p38Q. Furthermore, phos-
phorylation of Ser-3 had no e¡ect on the enzymatic activity
of activated p38Q,.
The identi¢cation of signi¢cant ATPase activity for p38Q led
us to probe other MAP kinases for a similar ability to turn
over ATP in the absence of a phosphoacceptor substrate.
ATPase activity was observed for all four MAP kinases tested
(p38K, ERK2 and JNK3, in addition to p38Q). This observa-
tion suggests that formation of a binary EbMgATP complex is
possible in the absence of a phosphoacceptor substrate. A
published mechanism for p38K described ordered substrate
binding with the phosphoacceptor substrate binding ¢rst
[23], but in light of our data in Fig. 1 and Table 2, such a
mechanism can be ruled out for p38K, p38Q, ERK2 and
JNK3. These data indicate that the phosphoacceptor can
not bind ¢rst. Substrate binding to p38Q involves either ATP
binding ¢rst, or random substrate binding, although these
data do not allow us to distinguish between the two latter
mechanisms.
Because of the apparent contradiction between our data
and those determined for p38K [23], we sought additional
experiments to study the ability of ATP to bind p38Q in the
absence of a phosphoacceptor. FSBA modi¢cation and com-
petition experiments with AMP-PCP provide further insight
into the ATP-binding site reactivity of this enzyme. FSBA is
an e¡ective a⁄nity label for the EGF receptor kinase
[24,28,29] and we found that it e⁄ciently and selectively modi-
¢ed the ATP site of p38Q MAP kinase. FSBA and AMP-PCP
di¡er structurally only in the triphosphate region (Fig. 3), so it
is interesting that FSBA binds more rapidly to unphosphory-
lated p38Q, i.e. the form which appears unable to bind AMP-
PCP. FSBA reactivity was also found to be independent of
Mg2 while AMP-PCP, as one might expect, required Mg2
to bind and protect activated p38Q against FSBA inactivation.
FSBA reactivity can be understood in the context of the
existing MAP kinase structures. The structures of activated
ERK2 and p38Q and of unphosphorylated p38K, ERK2 and
JNK3 have been determined [25,30^33]. While a comparison
of activated and unphosphorylated p38Q would be most rele-
vant to this study, the structure of unphosphorylated p38Q has
not been determined. p38K shares a high degree of sequence
identity with p38Q and so the structure of unphosphorylated
p38K can be compared with activated p38Q. The structures of
activated ERK2 and p38Q are almost identical to one another
and are characterized most generally by a closure of the two
kinase domains (relative to the unphosphorylated state). ATP
binds p38Q at the interface between these two domains and
this closure helps align the catalytic residues that coordinate
the ATP and Mg2 ions. All of the existing unphosphorylated
MAP kinase structures show the two kinase domains opened
to di¡ering extents relative to the activated state. Unphos-
phorylated p38K is the most open relative to activated p38Q
and ERK2, and di¡ers by about 20‡ from the activated state.
It seems reasonable that such a large conformational di¡er-
ence between the unphosphorylated and activated states of
p38Q could modulate the ability of FSBA and other ATP
analogs bind the active site. FSBA more readily binds to
the open unphosphorylated state of p38Q compared to the
closed activated form. The open unphosphorylated state
does not appear to bind AMP-PCP and thus AMP-PCP can
not compete with FSBA binding. AMP-PCP can however
compete with binding to the closed activated form, for which
it has a⁄nity. Additional competition experiments involving
FSBA may be useful to further probe the di¡erent conforma-
tional states of these enzymes. There are clearly signi¢cant
di¡erences between MAP kinases. For example, ERK2 and
JNK3 have both been shown to bind ATP or ATP analogs in
the inactive state [30,33]. In contrast, unphosphorylated p38
members do not appear to bind ATP or the non-hydrolyzable
analog, AMP-PCP.
We present data demonstrating that a phosphoacceptor
substrate does not have to bind prior to ATP in activated
p38K, p38Q, ERK2 and JNK3, since all of these enzymes ex-
hibit signi¢cant basal ATPase activity. The unphosphorylated
form of p38Q was unable to bind AMP-PCP unlike inactive
ERK2 and JNK3, which were both capable of binding ATP
or AMP-PCP. This suggests there may be signi¢cant structur-
al di¡erences between activation of members of the p38 class
compared to the ERK and JNK classes. None of the MAP
kinases in this study exhibited any measurable basal ATPase
activity in the unphosphorylated state. This study improves
our understanding of MAP kinase ATP-binding site reactivity
and provides new insight into the kinetic mechanism of this
family.
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